Coordination Complex for Synergistic Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current combination drug therapies often face challenges in ensuring effective synergistic delivery of multiple pharmaceutical agents, as seen in cases where one agent can interfere with the binding of another, leading to reduced efficacy or toxicity, and there is a lack of methods using metals to combine different pharmacophore fragments effectively.
Innovation Solution
The development of coordination complexes comprising a first and second biologically active moiety bound to a metal, forming a single molecular entity that enhances pharmacodynamic properties and allows for synergistic delivery to target tissues, leveraging metal coordination chemistry to stabilize the complex while maintaining biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple pharmaceutical agents are combined in a single molecular entity, then synergistic delivery and pharmacodynamic properties are enhanced, but the complexity of designing and manufacturing the complex increases
Solution Approach 1:
A metal ion serves as an intermediary to coordinate and hold multiple pharmacophore fragments in a stable complex structure, enabling synergistic delivery while simplifying the overall design compared to covalent conjugation approaches
Solution Approach 2:
The patent creates a composite molecular entity combining multiple pharmacophore fragments with a metal ion, leveraging the stabilizing properties of metal coordination chemistry to achieve both synergistic efficacy and structural stability
2Stability of the object's composition
If biologically active moieties are bound to a metal in a coordination complex, then stability and pharmacokinetic properties are improved, but the loss of free pharmacophore fragments may occur
Solution Approach 1:
The coordination complex is designed with dynamic binding characteristics, allowing the metal-pharmacophore bonds to remain stable during circulation while enabling controlled release at target sites through ligand exchange mechanisms
Solution Approach 2:
The patent utilizes changes in the coordination environment of the metal ion (such as ligand exchange with biological molecules) to control the release of pharmacophore fragments at the appropriate time and location
3Reliability
If combination drug therapy is used to treat disease states, then treatment efficacy and quality of life are improved, but the risk of interference between agents and toxicity increases
Solution Approach 1:
The patent segments the combination therapy into distinct pharmacophore fragments that are spatially separated around a central metal ion, preventing direct interference between agents while maintaining their synergistic therapeutic effects
Solution Approach 2:
The metal ion acts as a mediator that holds potentially interfering pharmacophore fragments in a controlled arrangement, allowing them to function synergistically while preventing harmful interactions between the agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables kinetically synergistic delivery of biologically active agents, improving their pharmacokinetic properties, stability, and efficacy by forming a single molecular entity that retains therapeutic effects while minimizing interference, thus enhancing treatment outcomes for various disease states.
Implementation Method 1
The development of coordination complexes comprising a first and second biologically active moiety bound to a metal, forming a single molecular entity that enhances pharmacodynamic properties
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety and second biologically active moiety are different. These complexes may enhance the pharmacodynamic properties of biologically active moieties.